Timing, Returns Record Right For Vivo Capital Fundraising

Once a lesser known firm in US life sciences investing, Vivo Capital has emerged as a global leader in biopharmaceutical and medtech start-ups, raising a $750 million fund that will be invested in the US, Europe, and China.

Whether in comedy or commerce, timing is everything, and Vivo Capital appears to have timed its recent fundraising just right. Founded in 1996 as BioAsia, Vivo Capital began as an anomaly in Silicon Valley, a life sciences venture firm investing Asian dollars into US-based biopharmaceutical and medical devices. A principle plank in the firm’s investing platform involved bringing a US-developed life sciences start-up mentality back to Asia, but the firm quickly identified the true opportunity – exporting US-made drugs and devices into China’s burgeoning health care system. (See Also see "Vivo Ventures’ Time Arrives As All Eyes Look To China" - In Vivo, 19 December, 2012..)

Fast forward nearly 20 years, and the former BioAsia – now Vivo Capital – has leveraged those Pan-Pacific connections to...

More from Archive

More from In Vivo